HC Wainwright & Co. Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $25
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $25.
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $25.